// App-Quantinova.ai

: Safety and efficacy of P2X3 antagonist BAY 1902607 in refractory chronic cough

Researchers

Presenter

  • Christian Friedrich

Principal Investigators

  • Klaus Francke

  • Surinder S Birring

  • J W K Van Den Berg

  • Paul Marsden

  • Lorcan Mcgarvey

  • Alice Turner

  • Pascal Wielders

  • Isabella Gashaw

  • Stefan Klein

  • Alyn Morice

Medical Centers

  • Bayer, Berlin, Germany

  • Centre for Human & Applied Physiological Sciences, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King’s College London, London, United Kingdom

  • Department of Hematology,Isala Hospital,Zwolle,Netherlands

  • Faculty of Medical and Human Sciences,The University of Manchester, Manchester, United Kingdom

  • Airway Innate Immunity Group, Wellcome Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry & Biomedical Sciences, Queen’s University Belfast, Belfast, United Kingdom

  • School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom

  • Department of Surgery, Catharina Hospital, Eindhoven, Netherlands

  • Hull York Medical School, University of Hull, Castle Hill Hospital, Cottingham, E Yorkshire, United Kingdom

Locations

  • Germany

  • United Kingdom

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Cross Over

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • NCT03535168

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved